Crossmark

Reduction of polycystic kidney and liver volumes in a patient with tolvaptan-resistant autosomal dominant polycystic kidney disease and acromegaly during lanreotide therapy

Crossref DOI link: https://doi.org/10.1007/s13730-025-01013-1

Published Online: 2025-06-27

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Takenaka, Shun

Hattanda, Fumihiko https://orcid.org/0009-0007-9486-9071
Kawamura, Takuro

Watanabe-Kusunoki, Kanako

Nakazawa, Daigo

Kameda, Hiraku

Amengual, Olga

Atsumi, Tatsuya

Nishio, Saori
License Information

Text and Data Mining valid from 2025-06-27

Version of Record valid from 2025-06-27
More Information

Article History

Received: 5 February 2025

Accepted: 12 June 2025

First Online: 27 June 2025

Declarations

:

: The authors have declared that no conflict of interest exists.

: This article contains no studies performed by authors with human participants or animals.

: Informed consent was obtained from this patient included in the study.

Document is current

Any future updates will be listed below